603392 万泰生物
已收盘 10-26 15:00:00
资讯
新帖
简况
图解万泰生物三季报：第三季度单季净利润同比下降248.68%
证券之星 · 01:20
图解万泰生物三季报：第三季度单季净利润同比下降248.68%
万泰生物最新公告：前三季度净亏损2.31亿元
证券之星 · 10-26 18:02
万泰生物最新公告：前三季度净亏损2.31亿元
万泰生物（603392）10月15日主力资金净买入174.64万元
证券之星 · 10-16
万泰生物（603392）10月15日主力资金净买入174.64万元
万泰生物（603392）10月13日主力资金净卖出944.05万元
证券之星 · 10-14
万泰生物（603392）10月13日主力资金净卖出944.05万元
股市必读：万泰生物新发布《万泰生物关于公司冻干重组呼吸道合胞病毒疫苗（CHO细胞）获得药物临床试验批准通知书的公告》
证券之星 · 10-14
股市必读：万泰生物新发布《万泰生物关于公司冻干重组呼吸道合胞病毒疫苗（CHO细胞）获得药物临床试验批准通知书的公告》
万泰生物：依托平台集群叠加大数据与AI工具实现新型疫苗抗原自主设计
证券之星 · 10-13
万泰生物：依托平台集群叠加大数据与AI工具实现新型疫苗抗原自主设计
万泰生物：鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险
证券之星 · 10-12
万泰生物：鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险
万泰生物：公司海外业务主要以美元作为计价结算币种
证券之星 · 10-12
万泰生物：公司海外业务主要以美元作为计价结算币种
万泰生物：公司后续会加强投资者沟通
证券之星 · 10-12
万泰生物：公司后续会加强投资者沟通
万泰生物：越南是公司HPV疫苗国际化布局的目标市场之一
证券之星 · 10-12
万泰生物：越南是公司HPV疫苗国际化布局的目标市场之一
万泰生物：公司有梅毒快速检测试剂盒相关产品
证券之星 · 10-12
万泰生物：公司有梅毒快速检测试剂盒相关产品
万泰生物：董事、高管减持属于个人财产安排
证券之星 · 10-12
万泰生物：董事、高管减持属于个人财产安排
万泰生物：梅毒诊断试剂暂未在日本实现销售
证券之星 · 10-12
万泰生物：梅毒诊断试剂暂未在日本实现销售
万泰生物：冻干重组呼吸道合胞病毒疫苗获临床试验批准
格隆汇 · 10-12
万泰生物：冻干重组呼吸道合胞病毒疫苗获临床试验批准
万泰生物(603392.SH)：冻干重组呼吸道合胞病毒疫苗(CHO细胞)获批临床试验
智通财经 · 10-12
万泰生物(603392.SH)：冻干重组呼吸道合胞病毒疫苗(CHO细胞)获批临床试验
股市必读：万泰生物新发布《万泰生物关于全资子公司通过土耳其GMP符合性检查的公告》
证券之星 · 10-12
股市必读：万泰生物新发布《万泰生物关于全资子公司通过土耳其GMP符合性检查的公告》
万泰生物（603392）披露全资子公司通过土耳其GMP符合性检查公告，10月09日股价上涨1.74%
证券之星 · 10-09
万泰生物（603392）披露全资子公司通过土耳其GMP符合性检查公告，10月09日股价上涨1.74%
“924”行情两周年记：一场“脱钩”的牛市，市值狂飙与基本面背离
财事汇 · 10-09
“924”行情两周年记：一场“脱钩”的牛市，市值狂飙与基本面背离
万泰生物（603392）9月28日主力资金净买入513.44万元
证券之星 · 09-29
万泰生物（603392）9月28日主力资金净买入513.44万元
万泰生物：二十价肺炎球菌多糖结合疫苗产业化项目相关费用已计入往期财报
证券之星 · 09-24
万泰生物：二十价肺炎球菌多糖结合疫苗产业化项目相关费用已计入往期财报
暂无数据
公司概况
公司名称：
北京万泰生物药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-04-29
主营业务：
北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。
发行价格：
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":25.79,"timestamp":1792998000000,"preClose":25.59,"halted":0,"volume":5585628,"delay":0,"changeRate":0.0078,"floatShares":1264000000,"shares":1264000000,"eps":-0.3604,"marketStatus":"已收盘","change":0.2,"latestTime":"10-26 15:00:00","open":25.45,"high":25.96,"low":25.41,"amount":144000000,"amplitude":0.0215,"askPrice":25.8,"askSize":17,"bidPrice":25.79,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-0.3604,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793064600000},"marketStatusCode":5,"adr":0,"adjPreClose":25.59,"symbolType":"stock","openAndCloseTimeList":[[1792978200000,1792985400000],[1792990800000,1792998000000]],"highLimit":28.15,"lowLimit":23.03,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1264392804,"isCdr":false,"pbRate":2.78,"roa":"--","roe":"--","epsLYR":-0.31,"committee":0.02799,"marketValue":32609000000,"turnoverRate":0.0044,"status":0,"floatMarketCap":32609000000},"requestUrl":"/m/hq/s/603392/tweets","defaultTab":"tweets","newsList":[{"id":"2678118597","title":"图解万泰生物三季报：第三季度单季净利润同比下降248.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678118597","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678118597?lang=zh_cn&edition=full","pubTime":"2026-10-27 01:20","pubTimestamp":1793035226,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物2026年三季报显示，前三季度公司主营收入16.23亿元，同比上升8.29%；归母净利润-2.31亿元，同比下降33.07%；扣非净利润-2.86亿元，同比上升6.99%；其中2026年第三季度，公司单季度主营收入5.74亿元，同比下降12.33%；单季度归母净利润-1.02亿元，同比下降248.68%；单季度扣非净利润-1.17亿元，同比下降80.33%；负债率12.97%，投资收益4468.55万元，财务费用1136.9万元，毛利率63.4%。财报数据概要请见下图:本文数据来源于万泰生物2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700002853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678615541","title":"万泰生物最新公告：前三季度净亏损2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678615541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678615541?lang=zh_cn&edition=full","pubTime":"2026-10-26 18:02","pubTimestamp":1793008959,"startTime":"0","endTime":"0","summary":"万泰生物(603392.SH)公告称，第三季度营业收入为5.74亿元，同比下降12.33%；归属于上市公司股东的净利润为-1.02亿元。前三季度营业收入为16.23亿元，同比增长8.29%；归属于上市公司股东的净利润为-2.31亿元。注：公司Q3净利润亏损1.02亿，Q2净利润-0.85亿，据此计算，Q3净利润环比持续亏损。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600024699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","LU1981816686.USD","BK1200","BK0239","BK1589","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675595245","title":"万泰生物（603392）10月15日主力资金净买入174.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675595245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675595245?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:16","pubTimestamp":1792109779,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，万泰生物报收于25.3元，上涨0.4%，换手率0.44%，成交量5.5万手，成交额1.39亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入598.63万元，融资偿还1338.39万元，融资净偿还739.76万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600007147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1200","BK1589","BK0239","LU1981816686.USD","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675396861","title":"万泰生物（603392）10月13日主力资金净卖出944.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675396861","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675396861?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:30","pubTimestamp":1791937854,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，万泰生物报收于25.74元，下跌2.17%，换手率0.42%，成交量5.3万手，成交额1.37亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入852.95万元，融资偿还1526.37万元，融资净偿还673.42万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","BK1589","09633","LU1981816686.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675369921","title":"股市必读：万泰生物新发布《万泰生物关于公司冻干重组呼吸道合胞病毒疫苗（CHO细胞）获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369921","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675369921?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:38","pubTimestamp":1791913090,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，万泰生物报收于25.74元，下跌2.17%，换手率0.42%，成交量5.3万手，成交额1.37亿元。公司公告汇总：万泰生物全资子公司冻干重组呼吸道合胞病毒疫苗获国家药监局临床试验批准，拟用于预防60岁及以上人群RSV所致下呼吸道疾病。公司高度重视人工智能技术与疫苗研发的深度融合。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","159646","BK0239","LU1981816686.USD","BK1589","09633","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675339464","title":"万泰生物：依托平台集群叠加大数据与AI工具实现新型疫苗抗原自主设计","url":"https://stock-news.laohu8.com/highlight/detail?id=2675339464","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675339464?lang=zh_cn&edition=full","pubTime":"2026-10-13 15:34","pubTimestamp":1791876888,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问邱总：请介绍一下，公司为生物疫苗人工智能究竟做了哪些具体性实质性的工作？万泰生物回复：您好！公司高度重视人工智能技术与疫苗研发的深度融合。在研发环节，依托公司搭建的覆盖疫苗研发全周期的抗原设计与临床前评价平台集群，叠加大数据与AI工具，实现新型疫苗抗原自主设计、专利壁垒突破和多维度临床前有效性验证，从源头提升创新疫苗管线临床申报转化率和商业化落地可行性。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300020593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","159646","603392","BK1589","09633","LU1981816686.USD","159739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674387302","title":"万泰生物：鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2674387302","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674387302?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796690,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物10月12日在投资者关系平台上答复投资者关心的问题。还有戊肝疫苗，5亿的研发成本，卖出不到100万剂。鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险；水痘疫苗项目仍在推进；戊肝疫苗作为全球首创产品，市场培育周期较长。公司重大项目均履行相应审议决策流程，管理层对公司经营承担勤勉尽责责任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","09633","603392","BK1589","BK0239","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873073","title":"万泰生物：公司海外业务主要以美元作为计价结算币种","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873073?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796688,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问：公司与泰国印尼等国家的收费是以人民币、美元还是当地货币结算，结算周期一般多长时间？谢谢。万泰生物回复：您好！公司海外业务主要以美元作为计价结算币种，结算周期根据不同业务模式有所区分。公司高度重视海外回款风险，通过投保出口信用保险、前置客户资质尽调、审慎选择合作方、合理约定付款条款、动态跟踪回款进度等方式保障海外收款安全。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1589","09633","LU1981816686.USD","BK1200","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674287302","title":"万泰生物：公司后续会加强投资者沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2674287302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674287302?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796688,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物10月12日在投资者关系平台上答复投资者关心的问题。在遵守信息披露监管要求的前提下，公司后续会加强投资者沟通。公司管理层将持续深耕主业，扎实做好经营，力争以长期业绩回报投资者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","BK1589","09633","LU1981816686.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873046","title":"万泰生物：越南是公司HPV疫苗国际化布局的目标市场之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873046?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796686,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，与我国接壤的越南，人口大国且经济情况良好，为何至今贵司的HPV疫苗还没有进入该国？ 是在准入方面遇到了困难了吗？万泰生物回复：您好！越南是公司HPV疫苗国际化布局的目标市场之一。但国际上各个国家的药品监管要求不同，准入时间周期也不同。根据越南当地药品监管要求，目前相关注册准入工作正按计划有序推进。公司将严格按照监管要求及时履行信息披露义务。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","BK1589","FVNmain","09633","LU1981816686.USD","BK1200","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873117","title":"万泰生物：公司有梅毒快速检测试剂盒相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873117?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:09","pubTimestamp":1791796152,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，目前有媒体报道了国外某国的梅毒激增，贵公司是否有生产梅毒快速检测试剂盒？目前梅毒快速试剂检测是否会出口？今年1至9月，贵公司的梅毒快速试剂检测盒的销量是否同比增长？谢谢万泰生物回复：您好！公司有梅毒快速检测试剂盒相关产品，该产品可对外出口。公司各类梅毒检测试剂包含化学发光、酶免、胶体金（快速检测）及质控品等多品类，产品出口覆盖亚、欧、非、拉美各大洲 20 多个国家和地区。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","LU1981816686.USD","BK1589","BK1200","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674114873","title":"万泰生物：董事、高管减持属于个人财产安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2674114873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674114873?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:09","pubTimestamp":1791796150,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价跌跌不休，屡创新低。身为管理层，非但不关心股价，不维护市值，反而在此时落井下石，刻意通过二级市场减持，严重影响了公司在资本市场的形象和口碑。公司对于这样的人员有何惩罚措施？万泰生物回复：您好！股价受多重因素影响。董事、高管减持属于个人财产安排，减持全过程符合监管规定，且已依规履行信息披露义务。管理层将持续聚焦主业，努力改善经营，维护股东长期利益。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1589","603392","LU1981816686.USD","BK1200","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873161","title":"万泰生物：梅毒诊断试剂暂未在日本实现销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873161?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:06","pubTimestamp":1791795967,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问：目前日本梅毒爆发，公司的梅毒诊断试剂在日本有销售布局吗？出口日本的量大吗？万泰生物回复：您好！目前公司在日本上市销售的为乙肝、丁肝、戊肝酶免检测试剂盒，梅毒诊断试剂暂未在日本实现销售。公司国际业务团队正密切关注日本梅毒市场动态，积极寻找合作伙伴，推进相关产品落地销售。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1589","09633","BK1200","603392","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674827021","title":"万泰生物：冻干重组呼吸道合胞病毒疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674827021","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674827021?lang=zh_cn&edition=full","pubTime":"2026-10-12 16:02","pubTimestamp":1791792160,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","159646","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674270708","title":"万泰生物(603392.SH)：冻干重组呼吸道合胞病毒疫苗(CHO细胞)获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2674270708","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674270708?lang=zh_cn&edition=full","pubTime":"2026-10-12 16:01","pubTimestamp":1791792078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司万泰沧海收到国家药监局核准签发的冻干重组呼吸道合胞病毒疫苗(CHO细胞)的《药物临床试验批准通知书》。同意开展预防60岁及以上人群由呼吸道合胞病毒(RSV)感染引起的下呼吸道疾病的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1200","PSYK","159646","BK1589","09633","IBBQ","BK0239","BMED","LU1981816686.USD","MDTX","IBBJ","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674845670","title":"股市必读：万泰生物新发布《万泰生物关于全资子公司通过土耳其GMP符合性检查的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674845670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674845670?lang=zh_cn&edition=full","pubTime":"2026-10-12 02:12","pubTimestamp":1791742334,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，万泰生物报收于26.96元，上涨1.74%，换手率0.54%，成交量6.77万手，成交额1.8亿元。当日关注点交易信息汇总：10月9日主力资金净流出944.25万元，占总成交额5.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","BK1589","LU1981816686.USD","603392","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674641850","title":"万泰生物（603392）披露全资子公司通过土耳其GMP符合性检查公告，10月09日股价上涨1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674641850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674641850?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:23","pubTimestamp":1791555798,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，万泰生物报收于26.96元，较前一交易日上涨1.74%，最新总市值为340.88亿元。近日，北京万泰生物药业股份有限公司全资子公司厦门万泰沧海生物技术有限公司的九价HPV疫苗生产线通过土耳其药品和医疗器械管理局GMP符合性检查，并获得TITCK颁发的GMP证书。此次通过检查标志着公司生产和质量管理体系首次通过PIC/S成员国的GMP符合性检查。PIC/S成员国间可实现GMP检查结果互认，但不构成市场准入或产品注册的自动批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900038416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","09633","603392","BK1589","BK0239","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674837427","title":"“924”行情两周年记：一场“脱钩”的牛市，市值狂飙与基本面背离","url":"https://stock-news.laohu8.com/highlight/detail?id=2674837427","media":"财事汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674837427?lang=zh_cn&edition=full","pubTime":"2026-10-09 16:35","pubTimestamp":1791534900,"startTime":"0","endTime":"0","summary":"2024年9月24日，A股在情绪冰点处被一纸政策点燃；两年后，总市值超120万亿，个股平均日均成交额近乎翻倍。前一轮行情中，A股市场股票数量从3338家激增至4028家，增幅高达20.67%，期间IPO共690家。前一轮行情中，A股总市值从46.27万亿飙升至88.28万亿，增幅接近翻倍，是大范围的“造富行情”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-10-09/doc-iniurmnf6838682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000858","LIT","300782","EVS.SI","600028","601398","688498","002568","603256","601288","688313","BK0214","603392","03750","LU0456827905.SGD","601888","LU0588546209.SGD","LU2506951792.HKD","300750","688585","IE00BYQNZ168.SGD","301618","LU0205439572.USD","000820","LU0082770016.USD","600036","SG9999003461.SGD","LU1105468828.SGD","601939","002791","PB","LU0516423174.USD","601633","600519","601857","002358","300760","002356","001279","300176","601988","603395","002370","LU2023250504.SGD","301377","300308","CXSE","LU1734074674.USD","300677","601138"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671138266","title":"万泰生物（603392）9月28日主力资金净买入513.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671138266","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671138266?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:22","pubTimestamp":1790641367,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，万泰生物报收于26.69元，上涨1.18%，换手率0.42%，成交量5.27万手，成交额1.39亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入1115.13万元，融资偿还1074.31万元，融资净买入40.82万元，连续3日净买入累计570.77万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1589","09633","BK1200","603392","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669464393","title":"万泰生物：二十价肺炎球菌多糖结合疫苗产业化项目相关费用已计入往期财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2669464393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669464393?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:24","pubTimestamp":1790245450,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：二十价肺炎球菌多糖结合疫苗产业化项目终止后，给合作方的费用以及临床费用是否已经在往期财报中已经体现，后续无需计提？万泰生物回复：您好！公司二十价肺炎球菌多糖结合疫苗产业化项目涉及的合作方款项及临床试验相关费用，均在实际发生时严格按照《企业会计准则》相关规定计入对应会计期间的当期费用，已完整体现在公司往期各期财报中，后续无需就该项目相关合作款项及临床试验费用进行额外计提。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","159646","09633"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793047313134,"stockEarnings":[{"period":"1week","weight":0.0316},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.1168},{"period":"6month","weight":-0.3399},{"period":"1year","weight":-0.5285},{"period":"ytd","weight":-0.4261}],"compareEarnings":[{"period":"1week","weight":-0.009},{"period":"1month","weight":-0.0491},{"period":"3month","weight":-0.0304},{"period":"6month","weight":-0.0998},{"period":"1year","weight":-0.064},{"period":"ytd","weight":-0.0684}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"46972人(较上一季度增加9.43%)","perCapita":"26918股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126439万元","survey":" 北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}